LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Celldex Therapeutics Inc

Ouvert

SecteurSoins de santé

20.4 1.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.5

Max

20.55

Chiffres clés

By Trading Economics

Revenu

-5M

-47M

Ventes

-480K

695K

BPA

-0.81

Marge bénéficiaire

-4,007.83

Employés

186

EBITDA

-3.9M

-55M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+197.41% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7.3M

1.3B

Ouverture précédente

18.71

Clôture précédente

20.4

Sentiment de l'Actualité

By Acuity

50%

50%

173 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Celldex Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 mai 2025, 22:52 UTC

Résultats
Principaux Mouvements du Marché

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mai 2025, 20:37 UTC

Actualités
Résultats

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mai 2025, 23:14 UTC

Actualités

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mai 2025, 22:46 UTC

Actualités
Acquisitions, Fusions, Rachats

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 21:58 UTC

Résultats

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mai 2025, 21:24 UTC

Résultats

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mai 2025, 20:54 UTC

Market Talk
Résultats

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mai 2025, 20:54 UTC

Résultats

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mai 2025, 20:51 UTC

Résultats

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 mai 2025, 20:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mai 2025, 20:50 UTC

Résultats

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mai 2025, 20:47 UTC

Résultats

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mai 2025, 20:47 UTC

Résultats

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mai 2025, 20:47 UTC

Résultats

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mai 2025, 20:47 UTC

Résultats

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mai 2025, 20:37 UTC

Résultats

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mai 2025, 20:37 UTC

Résultats

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mai 2025, 20:37 UTC

Résultats

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mai 2025, 20:37 UTC

Résultats

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mai 2025, 20:26 UTC

Actualités

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mai 2025, 20:25 UTC

Résultats

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparaison

Variation de prix

Celldex Therapeutics Inc prévision

Objectif de Prix

By TipRanks

197.41% hausse

Prévisions sur 12 Mois

Moyen 59.78 USD  197.41%

Haut 80 USD

Bas 36 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

18.91 / 20.63Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

173 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.